NR3C2 and hydrops fetalis: In a side-by-side comparison between the PARAGON-HF trial and the EMPEROR-Preserved trial [64], baseline characteristics were similar, including renal failure and diabetes prevalence, yet the former had higher EF (> 45% for eligibility, mean 57.5 ± 8.0%) than the latter (> 40% for eligibility, mean 54.3 ± 8.8%); moreover, in the PARAGON-HF, fewer patients were treated with beta-blockers (79.5%) and mineralocorticoid receptor antagonists (27.1%) than in the EMPEROR-Preserved trial (85.9% and 37.6%, respectively).